logo

For the Inventor, By the Inventor

Osaka, Japan

Ono Pharmaceutical Co., Ltd.


USPTO Granted Patents = 574



Trademarks = 16

Forward Citations = 6,343

Loading Chart...
Loading Chart...

800 inventors (with patents filed for the assignee):

goldMedal Shiro Shibayama (49 out of 52 patents)

silverMedal Masaki Hayashi (43 out of 46 patents)

bronzeMedal Yoshinobu Arai (40 out of 41 patents)

4.  Shuichi Ohuchida (40 out of 43 patents)

5.  Hiroyuki Ohno (31 out of 35 patents)

6.  Nobuyuki Hamanaka (30 out of 30 patents)

7.  Kousuke Tani (29 out of 32 patents)

8.  Tasuku Honjo (27 out of 40 patents)

9.  Masaaki Toda (27 out of 29 patents)

10.  Kaoru Kobayashi (24 out of 40 patents)

11.  Hisao Nakai (24 out of 25 patents)

12.  Katsuhiro Imaki (23 out of 23 patents)

13.  Kazuyuki Ohmoto (22 out of 27 patents)

14.  Jun Takeuchi (21 out of 23 patents)

15.  Yoshikazu Takaoka (21 out of 23 patents)


Core Competencies:
S1P5 Receptor Agonists
Immune Checkpoint Inhibitors
Bispecific Antibodies
KDM5 Inhibitors
Cancer Biomarkers
Chimeric Antigen Receptors
Combination Therapy
STING Agonists
HER2 Targeting Agents
TREK Channel Activators
ABHD6 Antagonists
Purinone Derivatives

574 patents:

1. 12459890 - Salt and crystal form of compound having agonistic activity to S1P5 receptor (2025-11-04),
2. 12447150 - Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy (2025-10-21),
3. 12325746 - Bispecific antibody (2025-06-10),
4. 12269817 - Compound having KDM5 inhibitory activity and pharmaceutical use thereof (2025-04-08),
5. 12258308 - Benzene derivative (2025-03-25),
6. 12240903 - Biomarkers for determining the effectiveness of immune checkpoint inhibitors (2025-03-04),
7. 12234289 - Immunosuppresive agent (2025-02-25),
8. 12201603 - Bicyclic compound and use thereof for medical purposes (2025-01-21),
9. 12186392 - Combination therapy of an anti CD20 antibody with a BTK inhibitor (2025-01-07),
10. 12152049 - STING agonistic compound (2024-11-26),
11. 12122846 - Chimeric antigen receptor for tumor targeting (2024-10-22),
12. 12091461 - Bispecific antibody (2024-09-17),
13. 12049445 - Compounds having S1P5 receptor agonistic activity (2024-07-30),
14. 12036204 - Pharmaceutical composition for treating tumor (2024-07-16),
15. 11981747 - HER2 targeting agent (2024-05-14),
ONO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company focuses on the research, development, manufacture, and sale of pharmaceutical products. It offers prescription pharmaceuticals, over-the-counter drugs, and diagnostic reagents. ONO PHARMACEUTICAL CO., LTD. operates both domestically and internationally, providing medical solutions in various therapeutic areas including oncology, immunology, and neurology.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

574 Patents

#40 in Osaka

#333 in Japan

#1,643 in the World

...
Osaka, Japan

Ono Pharmaceutical Co., Ltd.

Forward Citations = 6,343

800 inventors:

goldMedal Shiro Shibayama (49 out of 52 patents)

silverMedal Masaki Hayashi (43 out of 46 patents)

bronzeMedal Yoshinobu Arai (40 out of 41 patents)

4.  Shuichi Ohuchida (40 out of 43 patents)

5.  Hiroyuki Ohno (31 out of 35 patents)

Please report any incorrect information to support@idiyas.com
Loading…